Cisplatin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Cisplatin" in English language version.

refsWebsite

Global rank English rank

41nih.gov

4^th place

39doi.org

2^nd place

10semanticscholar.org

11^th place

8^th place

6handle.net

102^nd place

76^th place

5harvard.edu

18^th place

17^th place

4web.archive.org

1^st place

3fda.gov

447^th place

338^th place

2drugs.com

399^th place

333^rd place

2cancer.gov

1,684^th place

1,350^th place

2dcu.ie

low place

1books.google.com

3^rd place

1sciencedaily.com

993^rd place

920^th place

1neurosciencenews.com

low place

1acs.org

1,248^th place

1,104^th place

1matthey.com

low place

1zenodo.org

621^st place

380^th place

1eurekaselect.com

low place

1iucr.org

low place

9,593^rd place

1worldcat.org

5^th place

acs.org

pubs.acs.org

Trzaska S (20 June 2005). "Cisplatin". Chemical & Engineering News. 83 (25): 52. doi:10.1021/cen-v083n025.p052.

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 513. ISBN 9783527607495. Archived from the original on 20 December 2016.

cancer.gov

"Cisplatin". National Cancer Institute. 2 March 2007. Archived from the original on 8 October 2014. Retrieved 13 November 2014.
Winstead E (6 October 2022). "Sodium Thiosulfate Reduces Hearing Loss in Kids with Cancer". National Cancer Institute. Retrieved 9 March 2023.

dcu.ie

doras.dcu.ie

Stordal B, Davey M (November 2007). "Understanding cisplatin resistance using cellular models" (PDF). IUBMB Life. 59 (11): 696–699. doi:10.1080/15216540701636287. PMID 17885832. S2CID 30879019.
Stordal B, Pavlakis N, Davey R (December 2007). "A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship" (PDF). Cancer Treatment Reviews. 33 (8): 688–703. doi:10.1016/j.ctrv.2007.07.013. hdl:2123/4068. PMID 17881133.

doi.org

Oun R, Moussa YE, Wheate NJ (May 2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton Transactions. 47 (19): 6645–6653. doi:10.1039/c8dt00838h. PMID 29632935.
Callejo A, Sedó-Cabezón L, Juan ID, Llorens J (July 2015). "Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies". Toxics. 3 (3): 268–293. doi:10.3390/toxics3030268. PMC 5606684. PMID 29051464.
Einhorn LH (November 1990). "Treatment of testicular cancer: a new and improved model". Journal of Clinical Oncology. 8 (11): 1777–81. doi:10.1200/JCO.1990.8.11.1777. PMID 1700077.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (October 2010). "Mechanisms of Cisplatin Nephrotoxicity". Toxins. 2 (11): 2490–2518. doi:10.3390/toxins2112490. PMC 3153174. PMID 22069563.
Singh N, Vik A, Lybrand DB, Morisseau C, Hammock BD (November 2021). "New Alkoxy- Analogues of Epoxyeicosatrienoic Acids Attenuate Cisplatin Nephrotoxicity In Vitro via Reduction of Mitochondrial Dysfunction, Oxidative Stress, Mitogen-Activated Protein Kinase Signaling, and Caspase Activation". Chemical Research in Toxicology. 34 (12): 2579–2591. doi:10.1021/acs.chemrestox.1c00347. PMC 8853703. PMID 34817988.
Milosavljevic N, Duranton C, Djerbi N, Puech PH, Gounon P, Lagadic-Gossmann D, et al. (October 2010). "Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling". Cancer Research. 70 (19): 7514–22. doi:10.1158/0008-5472.CAN-10-1253. PMID 20841472.
Squillace S, Niehoff ML, Doyle TM, Green M, Esposito E, Cuzzocrea S, Arnatt CK, Spiegel S, Farr SA, Salvemini D (September 2022). "Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment". The Journal of Clinical Investigation. 132 (17). doi:10.1172/JCI157738. PMC 9433103. PMID 36047496.
Orgel E, Villaluna D, Krailo MD, Esbenshade A, Sung L, Freyer DR (May 2022). "Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431". The Lancet. Oncology. 23 (5): 570–572. doi:10.1016/S1470-2045(22)00155-3. PMC 9635495. PMID 35489339.
Sarafraz Z, Ahmadi A, Daneshi A (June 2018). "Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial". The International Tinnitus Journal. 22 (1): 40–45. doi:10.5935/0946-5448.20180007. PMID 29993216.
Levi JA, Aroney RS, Dalley DN (June 1981). "Haemolytic anaemia after cisplatin treatment". British Medical Journal. 282 (6281): 2003–4. doi:10.1136/bmj.282.6281.2003. PMC 1505958. PMID 6788166.
Wang D, Lippard SJ (April 2005). "Cellular processing of platinum anticancer drugs". Nature Reviews. Drug Discovery. 4 (4): 307–320. doi:10.1038/nrd1691. PMID 15789122. S2CID 31357727.
Johnstone TC, Suntharalingam K, Lippard SJ (March 2016). "The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs". Chemical Reviews. 116 (5): 3436–3486. doi:10.1021/acs.chemrev.5b00597. PMC 4792284. PMID 26865551.
Orbell JD, Solorzano C, Marzilli LG, Kistenmacher TJ (October 1982). "Preparation and structure of cis-chlorodiammine (N2, N2-dimethyl-9-methylguanine) platinum (II) hexafluorophosphate. A model for the intermediate in the proposed crosslinking mode of action of platinum (II) antitumor agents". Inorganic Chemistry. 21 (10): 3806–3810. doi:10.1021/ic00140a041.
Trzaska S (20 June 2005). "Cisplatin". Chemical & Engineering News. 83 (25): 52. doi:10.1021/cen-v083n025.p052.
Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J (June 2008). "Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells". Journal of Chemotherapy. 20 (3): 348–354. doi:10.1179/joc.2008.20.3.348. PMID 18606591. S2CID 11052459.
Sherman SE, Gibson D, Wang AH, Lippard SJ (October 1985). "X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]". Science. 230 (4724): 412–7. Bibcode:1985Sci...230..412S. doi:10.1126/science.4048939. PMID 4048939.
Hu J, Lieb JD, Sancar A, Adar S (October 2016). "Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution". PNAS. 113 (41): 11507–11512. Bibcode:2016PNAS..11311507H. doi:10.1073/pnas.1614430113. PMC 5068337. PMID 27688757. S2CID 11052459.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, et al. (May 2019). "Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition". Free Radical Biology & Medicine. 135: 167–181. doi:10.1016/j.freeradbiomed.2019.03.009. hdl:10486/688357. PMID 30880247.
Stordal B, Davey M (November 2007). "Understanding cisplatin resistance using cellular models" (PDF). IUBMB Life. 59 (11): 696–699. doi:10.1080/15216540701636287. PMID 17885832. S2CID 30879019.
Stordal B, Pavlakis N, Davey R (December 2007). "A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship" (PDF). Cancer Treatment Reviews. 33 (8): 688–703. doi:10.1016/j.ctrv.2007.07.013. hdl:2123/4068. PMID 17881133.
Coluccia M, Natile G (January 2007). "Trans-platinum complexes in cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 7 (1): 111–123. doi:10.2174/187152007779314080. PMID 17266508.
Kauffman GB, Pentimalli R, Hall MD (2010). "Michele Peyrone (1813–1883), Discoverer of Cisplatin". Platinum Metals Review. 54 (4): 250–256. doi:10.1595/147106710X534326. Retrieved 3 October 2022. This biographical article aims to present, for the first time in the English language, a summary of his life and the achievements that he made during his scientific career.
Peyrone M (1844). "Ueber die Einwirkung des Ammoniaks auf Platinchlorür" [On the action of ammonia on platinum chloride]. Ann. Chem. Pharm. 51 (1): 1–29. doi:10.1002/jlac.18440510102.
Rosenberg B, Vancamp L, Krigas T (February 1965). "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode". Nature. 205 (4972): 698–9. Bibcode:1965Natur.205..698R. doi:10.1038/205698a0. PMID 14287410. S2CID 9543916.
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ (March 1967). "The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes". The Journal of Biological Chemistry. 242 (6): 1347–52. doi:10.1016/S0021-9258(18)96186-7. PMID 5337590.
Rosenberg B, VanCamp L, Trosko JE, Mansour VH (April 1969). "Platinum compounds: a new class of potent antitumour agents". Nature. 222 (5191): 385–6. Bibcode:1969Natur.222..385R. doi:10.1038/222385a0. PMID 5782119. S2CID 32398470.
Wiltshaw E (1979). "Cisplatin in the treatment of cancer". Platinum Metals Review. 23 (3): 90–8. doi:10.1595/003214079X2339098. S2CID 267470502.
Kelland L (2007). "The resurgence of platinum-based cancer chemotherapy". Nature Reviews Cancer. 7 (8): 573–584. doi:10.1038/nrc2167. PMID 17625587. S2CID 205468214.
Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. (November 1994). "Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy". Journal of Neurosurgery. 81 (5): 690–8. doi:10.3171/jns.1994.81.5.0690. PMID 7931615.
Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. (March 1991). "Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma". Journal of Neurosurgery. 74 (3): 433–40. doi:10.3171/jns.1991.74.3.0433. PMID 1847194.
Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ (October 2009). "Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads". Journal of the American Chemical Society. 131 (41): 14652–3. doi:10.1021/ja9071282. PMC 2761975. PMID 19778015.
Santi M, Mapanao AK, Cassano D, Vlamidis Y, Cappello V, Voliani V (April 2020). "Endogenously-Activated Ultrasmall-in-Nano Therapeutics: Assessment on 3D Head and Neck Squamous Cell Carcinomas". Cancers. 12 (5): 1063. doi:10.3390/cancers12051063. PMC 7281743. PMID 32344838.
Alderden RA, Hall MD, Hambley TW (2006). "The Discovery and Development of Cisplatin". J. Chem. Educ. 83 (5): 728. Bibcode:2006JChEd..83..728A. doi:10.1021/ed083p728. S2CID 29546931.
Kukushikin VY, Oskarsson Å, Elding LI, Farrell N (2007). "Facile Synthesis of Isomerically Pure cis -Dichlorodiammineplatinum(II), Cisplatin". Facile Synthesis of Isomerically Pure cis -Dichlorodiammineplatinum(II), Cisplatin. Inorganic Syntheses. Vol. 32. pp. 141–144. doi:10.1002/9780470132630.ch23. ISBN 9780470132630.
Ku A, Facca VJ, Cai Z, Reilly RM (October 2019). "Auger electrons for cancer therapy - a review". EJNMMI Radiopharmacy and Chemistry. 4 (1): 27. doi:10.1186/s41181-019-0075-2. PMC 6800417. PMID 31659527.
Fiuza SM, Amado AM, Oliveira PJ, Sardão VA, De Carvalho LB, Marques MP (2006). "Pt(II) vs Pd(II) Polyamine Complexes as New Anticancer Drugs: A Structure- Activity Study". Letters in Drug Design & Discovery. 3 (3): 149–151. doi:10.2174/157018006776286989. hdl:10316/45139.
Teixeira LJ, Seabra M, Reis E, da Cruz MT, de Lima MC, Pereira E, et al. (May 2004). "Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates". Journal of Medicinal Chemistry. 47 (11): 2917–2925. doi:10.1021/jm0311238. hdl:10316/10605. PMID 15139770.
Vinci D, Chateigner D (1 December 2022). "Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt 2 Cl 4 (NH 3 ) 2 {μ-HN=C(O)Bu t } 2 ]". Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials. 78 (6): 835–841. doi:10.1107/S2052520622009660. ISSN 2052-5206. PMC 9728019.
Omondi RO, Ojwach SO, Jaganyi D (November 2020). "Review of comparative studies of cytotoxic activities of Pt(II), Pd(II), Ru(II)/(III) and Au(III) complexes, their kinetics of ligand substitution reactions and DNA/BSA interactions". Inorganica Chimica Acta. 512: 119883. doi:10.1016/j.ica.2020.119883. S2CID 225575546.

drugs.com

"Cisplatin Use During Pregnancy". Drugs.com. 12 September 2019. Retrieved 25 February 2020.
"Cisplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.

eurekaselect.com

Fiuza SM, Amado AM, Oliveira PJ, Sardão VA, De Carvalho LB, Marques MP (2006). "Pt(II) vs Pd(II) Polyamine Complexes as New Anticancer Drugs: A Structure- Activity Study". Letters in Drug Design & Discovery. 3 (3): 149–151. doi:10.2174/157018006776286989. hdl:10316/45139.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

fda.gov

"FDA approves sodium thiosulfate to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors". Food and Drug Administration. 20 September 2022. Retrieved 9 March 2023.

accessdata.fda.gov

"Approval Summary for cisplatin for Metastatic ovarian tumors". FDA Oncology Tools. Food and Drug Administration, Center for Drug Evaluation and Research. 19 December 1978. Archived from the original on 8 February 2008. Retrieved 15 July 2009.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, et al. (May 2019). "Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition". Free Radical Biology & Medicine. 135: 167–181. doi:10.1016/j.freeradbiomed.2019.03.009. hdl:10486/688357. PMID 30880247.
Stordal B, Pavlakis N, Davey R (December 2007). "A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship" (PDF). Cancer Treatment Reviews. 33 (8): 688–703. doi:10.1016/j.ctrv.2007.07.013. hdl:2123/4068. PMID 17881133.
Fiuza SM, Amado AM, Oliveira PJ, Sardão VA, De Carvalho LB, Marques MP (2006). "Pt(II) vs Pd(II) Polyamine Complexes as New Anticancer Drugs: A Structure- Activity Study". Letters in Drug Design & Discovery. 3 (3): 149–151. doi:10.2174/157018006776286989. hdl:10316/45139.
Teixeira LJ, Seabra M, Reis E, da Cruz MT, de Lima MC, Pereira E, et al. (May 2004). "Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates". Journal of Medicinal Chemistry. 47 (11): 2917–2925. doi:10.1021/jm0311238. hdl:10316/10605. PMID 15139770.

harvard.edu

ui.adsabs.harvard.edu

Sherman SE, Gibson D, Wang AH, Lippard SJ (October 1985). "X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]". Science. 230 (4724): 412–7. Bibcode:1985Sci...230..412S. doi:10.1126/science.4048939. PMID 4048939.
Hu J, Lieb JD, Sancar A, Adar S (October 2016). "Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution". PNAS. 113 (41): 11507–11512. Bibcode:2016PNAS..11311507H. doi:10.1073/pnas.1614430113. PMC 5068337. PMID 27688757. S2CID 11052459.
Rosenberg B, Vancamp L, Krigas T (February 1965). "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode". Nature. 205 (4972): 698–9. Bibcode:1965Natur.205..698R. doi:10.1038/205698a0. PMID 14287410. S2CID 9543916.
Rosenberg B, VanCamp L, Trosko JE, Mansour VH (April 1969). "Platinum compounds: a new class of potent antitumour agents". Nature. 222 (5191): 385–6. Bibcode:1969Natur.222..385R. doi:10.1038/222385a0. PMID 5782119. S2CID 32398470.
Alderden RA, Hall MD, Hambley TW (2006). "The Discovery and Development of Cisplatin". J. Chem. Educ. 83 (5): 728. Bibcode:2006JChEd..83..728A. doi:10.1021/ed083p728. S2CID 29546931.

iucr.org

scripts.iucr.org

Vinci D, Chateigner D (1 December 2022). "Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt 2 Cl 4 (NH 3 ) 2 {μ-HN=C(O)Bu t } 2 ]". Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials. 78 (6): 835–841. doi:10.1107/S2052520622009660. ISSN 2052-5206. PMC 9728019.

matthey.com

technology.matthey.com

Kauffman GB, Pentimalli R, Hall MD (2010). "Michele Peyrone (1813–1883), Discoverer of Cisplatin". Platinum Metals Review. 54 (4): 250–256. doi:10.1595/147106710X534326. Retrieved 3 October 2022. This biographical article aims to present, for the first time in the English language, a summary of his life and the achievements that he made during his scientific career.

neurosciencenews.com

"Unlocking the Mystery of "Chemo Brain"". Neuroscience News. 2 September 2022.

nih.gov

pubmed.ncbi.nlm.nih.gov

Oun R, Moussa YE, Wheate NJ (May 2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton Transactions. 47 (19): 6645–6653. doi:10.1039/c8dt00838h. PMID 29632935.
Callejo A, Sedó-Cabezón L, Juan ID, Llorens J (July 2015). "Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies". Toxics. 3 (3): 268–293. doi:10.3390/toxics3030268. PMC 5606684. PMID 29051464.
Einhorn LH (November 1990). "Treatment of testicular cancer: a new and improved model". Journal of Clinical Oncology. 8 (11): 1777–81. doi:10.1200/JCO.1990.8.11.1777. PMID 1700077.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (October 2010). "Mechanisms of Cisplatin Nephrotoxicity". Toxins. 2 (11): 2490–2518. doi:10.3390/toxins2112490. PMC 3153174. PMID 22069563.
Singh N, Vik A, Lybrand DB, Morisseau C, Hammock BD (November 2021). "New Alkoxy- Analogues of Epoxyeicosatrienoic Acids Attenuate Cisplatin Nephrotoxicity In Vitro via Reduction of Mitochondrial Dysfunction, Oxidative Stress, Mitogen-Activated Protein Kinase Signaling, and Caspase Activation". Chemical Research in Toxicology. 34 (12): 2579–2591. doi:10.1021/acs.chemrestox.1c00347. PMC 8853703. PMID 34817988.
Milosavljevic N, Duranton C, Djerbi N, Puech PH, Gounon P, Lagadic-Gossmann D, et al. (October 2010). "Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling". Cancer Research. 70 (19): 7514–22. doi:10.1158/0008-5472.CAN-10-1253. PMID 20841472.
Squillace S, Niehoff ML, Doyle TM, Green M, Esposito E, Cuzzocrea S, Arnatt CK, Spiegel S, Farr SA, Salvemini D (September 2022). "Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment". The Journal of Clinical Investigation. 132 (17). doi:10.1172/JCI157738. PMC 9433103. PMID 36047496.
Orgel E, Villaluna D, Krailo MD, Esbenshade A, Sung L, Freyer DR (May 2022). "Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431". The Lancet. Oncology. 23 (5): 570–572. doi:10.1016/S1470-2045(22)00155-3. PMC 9635495. PMID 35489339.
Sarafraz Z, Ahmadi A, Daneshi A (June 2018). "Transtympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-Induced Ototoxicity: Double Blind Randomized Clinical Trial". The International Tinnitus Journal. 22 (1): 40–45. doi:10.5935/0946-5448.20180007. PMID 29993216.
Levi JA, Aroney RS, Dalley DN (June 1981). "Haemolytic anaemia after cisplatin treatment". British Medical Journal. 282 (6281): 2003–4. doi:10.1136/bmj.282.6281.2003. PMC 1505958. PMID 6788166.
Wang D, Lippard SJ (April 2005). "Cellular processing of platinum anticancer drugs". Nature Reviews. Drug Discovery. 4 (4): 307–320. doi:10.1038/nrd1691. PMID 15789122. S2CID 31357727.
Johnstone TC, Suntharalingam K, Lippard SJ (March 2016). "The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs". Chemical Reviews. 116 (5): 3436–3486. doi:10.1021/acs.chemrev.5b00597. PMC 4792284. PMID 26865551.
Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J (June 2008). "Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells". Journal of Chemotherapy. 20 (3): 348–354. doi:10.1179/joc.2008.20.3.348. PMID 18606591. S2CID 11052459.
Sherman SE, Gibson D, Wang AH, Lippard SJ (October 1985). "X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]". Science. 230 (4724): 412–7. Bibcode:1985Sci...230..412S. doi:10.1126/science.4048939. PMID 4048939.
Hu J, Lieb JD, Sancar A, Adar S (October 2016). "Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution". PNAS. 113 (41): 11507–11512. Bibcode:2016PNAS..11311507H. doi:10.1073/pnas.1614430113. PMC 5068337. PMID 27688757. S2CID 11052459.
Cruz-Bermúdez A, Laza-Briviesca R, Vicente-Blanco RJ, García-Grande A, Coronado MJ, Laine-Menéndez S, et al. (May 2019). "Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition". Free Radical Biology & Medicine. 135: 167–181. doi:10.1016/j.freeradbiomed.2019.03.009. hdl:10486/688357. PMID 30880247.
Stordal B, Davey M (November 2007). "Understanding cisplatin resistance using cellular models" (PDF). IUBMB Life. 59 (11): 696–699. doi:10.1080/15216540701636287. PMID 17885832. S2CID 30879019.
Stordal B, Pavlakis N, Davey R (December 2007). "A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship" (PDF). Cancer Treatment Reviews. 33 (8): 688–703. doi:10.1016/j.ctrv.2007.07.013. hdl:2123/4068. PMID 17881133.
Coluccia M, Natile G (January 2007). "Trans-platinum complexes in cancer therapy". Anti-Cancer Agents in Medicinal Chemistry. 7 (1): 111–123. doi:10.2174/187152007779314080. PMID 17266508.
Rosenberg B, Vancamp L, Krigas T (February 1965). "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode". Nature. 205 (4972): 698–9. Bibcode:1965Natur.205..698R. doi:10.1038/205698a0. PMID 14287410. S2CID 9543916.
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ (March 1967). "The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes". The Journal of Biological Chemistry. 242 (6): 1347–52. doi:10.1016/S0021-9258(18)96186-7. PMID 5337590.
Rosenberg B, VanCamp L, Trosko JE, Mansour VH (April 1969). "Platinum compounds: a new class of potent antitumour agents". Nature. 222 (5191): 385–6. Bibcode:1969Natur.222..385R. doi:10.1038/222385a0. PMID 5782119. S2CID 32398470.
Kelland L (2007). "The resurgence of platinum-based cancer chemotherapy". Nature Reviews Cancer. 7 (8): 573–584. doi:10.1038/nrc2167. PMID 17625587. S2CID 205468214.
Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. (November 1994). "Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy". Journal of Neurosurgery. 81 (5): 690–8. doi:10.3171/jns.1994.81.5.0690. PMID 7931615.
Packer RJ, Sutton LN, Goldwein JW, Perilongo G, Bunin G, Ryan J, et al. (March 1991). "Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma". Journal of Neurosurgery. 74 (3): 433–40. doi:10.3171/jns.1991.74.3.0433. PMID 1847194.
Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ (October 2009). "Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads". Journal of the American Chemical Society. 131 (41): 14652–3. doi:10.1021/ja9071282. PMC 2761975. PMID 19778015.
Santi M, Mapanao AK, Cassano D, Vlamidis Y, Cappello V, Voliani V (April 2020). "Endogenously-Activated Ultrasmall-in-Nano Therapeutics: Assessment on 3D Head and Neck Squamous Cell Carcinomas". Cancers. 12 (5): 1063. doi:10.3390/cancers12051063. PMC 7281743. PMID 32344838.
Ku A, Facca VJ, Cai Z, Reilly RM (October 2019). "Auger electrons for cancer therapy - a review". EJNMMI Radiopharmacy and Chemistry. 4 (1): 27. doi:10.1186/s41181-019-0075-2. PMC 6800417. PMID 31659527.
Teixeira LJ, Seabra M, Reis E, da Cruz MT, de Lima MC, Pereira E, et al. (May 2004). "Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum(II) chelates". Journal of Medicinal Chemistry. 47 (11): 2917–2925. doi:10.1021/jm0311238. hdl:10316/10605. PMID 15139770.

ncbi.nlm.nih.gov

Callejo A, Sedó-Cabezón L, Juan ID, Llorens J (July 2015). "Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies". Toxics. 3 (3): 268–293. doi:10.3390/toxics3030268. PMC 5606684. PMID 29051464.
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (October 2010). "Mechanisms of Cisplatin Nephrotoxicity". Toxins. 2 (11): 2490–2518. doi:10.3390/toxins2112490. PMC 3153174. PMID 22069563.
Singh N, Vik A, Lybrand DB, Morisseau C, Hammock BD (November 2021). "New Alkoxy- Analogues of Epoxyeicosatrienoic Acids Attenuate Cisplatin Nephrotoxicity In Vitro via Reduction of Mitochondrial Dysfunction, Oxidative Stress, Mitogen-Activated Protein Kinase Signaling, and Caspase Activation". Chemical Research in Toxicology. 34 (12): 2579–2591. doi:10.1021/acs.chemrestox.1c00347. PMC 8853703. PMID 34817988.
Squillace S, Niehoff ML, Doyle TM, Green M, Esposito E, Cuzzocrea S, Arnatt CK, Spiegel S, Farr SA, Salvemini D (September 2022). "Sphingosine-1-phosphate receptor 1 activation in the central nervous system drives cisplatin-induced cognitive impairment". The Journal of Clinical Investigation. 132 (17). doi:10.1172/JCI157738. PMC 9433103. PMID 36047496.
Orgel E, Villaluna D, Krailo MD, Esbenshade A, Sung L, Freyer DR (May 2022). "Sodium thiosulfate for prevention of cisplatin-induced hearing loss: updated survival from ACCL0431". The Lancet. Oncology. 23 (5): 570–572. doi:10.1016/S1470-2045(22)00155-3. PMC 9635495. PMID 35489339.
Levi JA, Aroney RS, Dalley DN (June 1981). "Haemolytic anaemia after cisplatin treatment". British Medical Journal. 282 (6281): 2003–4. doi:10.1136/bmj.282.6281.2003. PMC 1505958. PMID 6788166.
Johnstone TC, Suntharalingam K, Lippard SJ (March 2016). "The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs". Chemical Reviews. 116 (5): 3436–3486. doi:10.1021/acs.chemrev.5b00597. PMC 4792284. PMID 26865551.
Hu J, Lieb JD, Sancar A, Adar S (October 2016). "Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution". PNAS. 113 (41): 11507–11512. Bibcode:2016PNAS..11311507H. doi:10.1073/pnas.1614430113. PMC 5068337. PMID 27688757. S2CID 11052459.
Dhar S, Daniel WL, Giljohann DA, Mirkin CA, Lippard SJ (October 2009). "Polyvalent oligonucleotide gold nanoparticle conjugates as delivery vehicles for platinum(IV) warheads". Journal of the American Chemical Society. 131 (41): 14652–3. doi:10.1021/ja9071282. PMC 2761975. PMID 19778015.
Santi M, Mapanao AK, Cassano D, Vlamidis Y, Cappello V, Voliani V (April 2020). "Endogenously-Activated Ultrasmall-in-Nano Therapeutics: Assessment on 3D Head and Neck Squamous Cell Carcinomas". Cancers. 12 (5): 1063. doi:10.3390/cancers12051063. PMC 7281743. PMID 32344838.
Ku A, Facca VJ, Cai Z, Reilly RM (October 2019). "Auger electrons for cancer therapy - a review". EJNMMI Radiopharmacy and Chemistry. 4 (1): 27. doi:10.1186/s41181-019-0075-2. PMC 6800417. PMID 31659527.
Vinci D, Chateigner D (1 December 2022). "Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt 2 Cl 4 (NH 3 ) 2 {μ-HN=C(O)Bu t } 2 ]". Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials. 78 (6): 835–841. doi:10.1107/S2052520622009660. ISSN 2052-5206. PMC 9728019.

sciencedaily.com

Milosavljevic N, Duranton C, Djerbi N, Puech PH, Gounon P, Lagadic-Gossmann D, et al. (October 2010). "Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling". Cancer Research. 70 (19): 7514–22. doi:10.1158/0008-5472.CAN-10-1253. PMID 20841472.

semanticscholar.org

api.semanticscholar.org

Wang D, Lippard SJ (April 2005). "Cellular processing of platinum anticancer drugs". Nature Reviews. Drug Discovery. 4 (4): 307–320. doi:10.1038/nrd1691. PMID 15789122. S2CID 31357727.
Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J (June 2008). "Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells". Journal of Chemotherapy. 20 (3): 348–354. doi:10.1179/joc.2008.20.3.348. PMID 18606591. S2CID 11052459.
Hu J, Lieb JD, Sancar A, Adar S (October 2016). "Cisplatin DNA damage and repair maps of the human genome at single-nucleotide resolution". PNAS. 113 (41): 11507–11512. Bibcode:2016PNAS..11311507H. doi:10.1073/pnas.1614430113. PMC 5068337. PMID 27688757. S2CID 11052459.
Stordal B, Davey M (November 2007). "Understanding cisplatin resistance using cellular models" (PDF). IUBMB Life. 59 (11): 696–699. doi:10.1080/15216540701636287. PMID 17885832. S2CID 30879019.
Rosenberg B, Vancamp L, Krigas T (February 1965). "Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode". Nature. 205 (4972): 698–9. Bibcode:1965Natur.205..698R. doi:10.1038/205698a0. PMID 14287410. S2CID 9543916.
Rosenberg B, VanCamp L, Trosko JE, Mansour VH (April 1969). "Platinum compounds: a new class of potent antitumour agents". Nature. 222 (5191): 385–6. Bibcode:1969Natur.222..385R. doi:10.1038/222385a0. PMID 5782119. S2CID 32398470.
Wiltshaw E (1979). "Cisplatin in the treatment of cancer". Platinum Metals Review. 23 (3): 90–8. doi:10.1595/003214079X2339098. S2CID 267470502.
Kelland L (2007). "The resurgence of platinum-based cancer chemotherapy". Nature Reviews Cancer. 7 (8): 573–584. doi:10.1038/nrc2167. PMID 17625587. S2CID 205468214.
Alderden RA, Hall MD, Hambley TW (2006). "The Discovery and Development of Cisplatin". J. Chem. Educ. 83 (5): 728. Bibcode:2006JChEd..83..728A. doi:10.1021/ed083p728. S2CID 29546931.
Omondi RO, Ojwach SO, Jaganyi D (November 2020). "Review of comparative studies of cytotoxic activities of Pt(II), Pd(II), Ru(II)/(III) and Au(III) complexes, their kinetics of ligand substitution reactions and DNA/BSA interactions". Inorganica Chimica Acta. 512: 119883. doi:10.1016/j.ica.2020.119883. S2CID 225575546.

web.archive.org

"Cisplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 513. ISBN 9783527607495. Archived from the original on 20 December 2016.
"Cisplatin". National Cancer Institute. 2 March 2007. Archived from the original on 8 October 2014. Retrieved 13 November 2014.
"Approval Summary for cisplatin for Metastatic ovarian tumors". FDA Oncology Tools. Food and Drug Administration, Center for Drug Evaluation and Research. 19 December 1978. Archived from the original on 8 February 2008. Retrieved 15 July 2009.

worldcat.org

Vinci D, Chateigner D (1 December 2022). "Synthesis and structural characterization of a new dinuclear platinum(III) complex, [Pt 2 Cl 4 (NH 3 ) 2 {μ-HN=C(O)Bu t } 2 ]". Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials. 78 (6): 835–841. doi:10.1107/S2052520622009660. ISSN 2052-5206. PMC 9728019.

zenodo.org

Peyrone M (1844). "Ueber die Einwirkung des Ammoniaks auf Platinchlorür" [On the action of ammonia on platinum chloride]. Ann. Chem. Pharm. 51 (1): 1–29. doi:10.1002/jlac.18440510102.